title: Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
abstract: OBJECTIVE
  Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response predicts pathological response to a standardised neoadjuvant chemotherapy regimen within a prospective clinical trial.
  
  
  METHODS
  Consecutive patients staged with potentially curable oesophageal cancer who underwent treatment within a non-randomised clinical trial were included. A standardised chemotherapy regimen (two cycles of oxaliplatin and 5-fluorouracil) was used. PET/CT was performed before chemotherapy and repeated 24-28 days after the start of cycle 2.
  
  
  RESULTS
  Forty-eight subjects were included: mean age 65 years; 37 male. Using the median percentage reduction in SUV(max) (42%) to define metabolic response, pathological response was seen in 71% of metabolic responders (17/24) compared with 33% of non-responders (8/24; P = 0.009, sensitivity 68%, specificity 70%). Pathological response was seen in 81% of subjects with a complete metabolic response (13/16) compared with 38% of those with a less than complete response (12/32; P = 0.0042, sensitivity 52%, specificity 87%). There was no significant histology-based effect.
  
  
  CONCLUSIONS
  There was a significant association between metabolic response and pathological response; however, accuracy in predicting pathological response was relatively low.
authors.affiliation: Department of Oncology, Oxford Cancer & Haematology Centre, Oxford, UK. rgillies@doctors.org.uk
authors.forename: R S
authors.initials: RS
authors.lastname: Gillies
authors.forename: M R
authors.initials: MR
authors.lastname: Middleton
authors.forename: C
authors.initials: C
authors.lastname: Blesing
authors.forename: K
authors.initials: K
authors.lastname: Patel
authors.forename: N
authors.initials: N
authors.lastname: Warner
authors.forename: R E K
authors.initials: RE
authors.lastname: Marshall
authors.forename: N D
authors.initials: ND
authors.lastname: Maynard
authors.forename: K M
authors.initials: KM
authors.lastname: Bradley
authors.forename: F V
authors.initials: FV
authors.lastname: Gleeson
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D064847:Multimodal Imaging / Q000379:methods*; D020360:Neoadjuvant Therapy / Q000379:methods; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18